Welcome to our dedicated page for Regen Biopharma SEC filings (Ticker: RGBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regen BioPharma, Inc. (RGBP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Regen BioPharma is a Nevada-incorporated biotechnology company focused on immunology and immunotherapy, including autologous cell therapies, RNA and DNA therapeutics, RNA vaccines, and small molecule drugs. Its filings offer insight into capital formation, equity structure, and agreements tied to its lead program, HemaXellerate.
Recent Form 8-K reports detail unregistered sales of equity securities under a Tier 2 Regulation A offering, including common share issuances for cash to unaffiliated investors, with proceeds designated for working capital. Other 8-Ks describe share issuances in satisfaction of principal and accrued interest on convertible indebtedness, illustrating how Regen BioPharma manages financing through equity and debt conversion.
Filings also disclose material definitive agreements related to the planned Phase I clinical trial of HemaXellerate. For example, Regen BioPharma has reported consulting and compensation agreements under which consultants and the company’s Chairman and Chief Executive Officer received newly issued common shares subject to vesting and transfer restrictions that depend on successful completion of the planned Phase I trial. These documents provide context on how equity incentives are linked to clinical development milestones.
Through this page, users can review historical information on common shares outstanding at specific dates, exemptions relied upon for securities offerings, and the legal basis for share issuances under Regulation A and Section 4(a)(2) of the Securities Act. Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, highlight changes in share count and financing terms, and help readers understand how reported agreements and offerings relate to Regen BioPharma’s clinical and corporate objectives.
Regen Biopharma, Inc. announced a special stock dividend in the form of its authorized but unissued Series A Preferred Stock. Shareholders of record on February 3, 2026 are scheduled to receive the dividend on or about February 9, 2026.
Each eligible holder will receive one share of Series A Preferred Stock for every one share of Regen Biopharma common stock, Series A Preferred Stock, Series AA Preferred Stock, Series M Preferred Stock, and Series NC Preferred Stock owned as of the record date. The dividend is paid entirely in shares, not cash, and applies across these listed classes of the company’s stock.
Regen Biopharma, Inc. is an early-stage Nevada biotech focused on regenerative medicine and immuno-oncology, with no clinical trials yet started and no conclusions of efficacy for its product candidates. The company is developing several NR2F6‑targeted programs, including HemaXellerate for severe aplastic anemia, dCellVax and tCellVax cell therapies, DiffronC and DuraCar for solid tumors, plus small‑molecule NR2F6 modulators, all in pre‑clinical or IND‑stage development.
Regen controls a portfolio of issued U.S. patents around NR2F6 modulation, cancer vaccines, and gene‑silencing technologies and monetizes some of this IP through licenses, notably to Zander Therapeutics for veterinary uses and to Oncology Pharma for human pancreatic and colon cancer indications, with upfront fees, royalties of 4–5% of Net Sales, and 10% of sublicense consideration. As of December 26, 2025, the company had 108,054,704 common shares outstanding and multiple preferred series, following a 1‑for‑1500 reverse split and a 2024 Series A preferred stock dividend, and continues to fund operations through Regulation A offerings, convertible notes, and share issuances for debt settlement and consulting services.
Regen BioPharma, Inc. filed an 8‑K disclosing unregistered sales of common stock. The company issued 6,800,000 shares on October 8, 2025 for $68,000 under a Tier 2 Regulation A offering sold directly by management.
On October 27, 2025, it issued 3,500,000 shares for $35,000 via Tier 2 Regulation A, and separately issued 4,500,000 shares to satisfy $30,204 of principal and $13,536 of accrued interest on convertible indebtedness under Section 4(a)(2), with no underwriters, commissions, or general solicitation.
On October 28, 2025, Regen issued 7,100,000 shares for $71,000 via Tier 2 Regulation A, and on November 10, 2025, it issued 1,780,000 shares for $17,800 via Tier 2 Regulation A. All Tier 2 Regulation A sales were conducted directly through management.
Regen BioPharma, Inc. disclosed that it raised cash through several unregistered sales of common stock to unaffiliated investors in mid-September
The shares were issued in reliance on Regulation A exemptions from registration under the Securities Act of 1933. No underwriters were involved, the sales were conducted directly by management without commissions or other consideration paid, and the company states that proceeds from each sale will be used for working capital.
FAQ
What is the current stock price of Regen Biopharma (RGBP)?
What is the market cap of Regen Biopharma (RGBP)?
